FORM 6-K
Report of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For March 2006
Commission File Number: 001-11960
AstraZeneca PLC
15 Stanhope Gate, London W1K 1LN, England
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
| Form 20-F X | Form 40-F |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
| Yes | No X |
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
AstraZeneca
PLC
INDEX TO EXHIBITS
| 1. | Press release entitled, “Dealing by Directors Companies Act 1985 Sections 324 / 329 Transaction by Persons Discharging Managerial Responsibilities Disclosure Rules DR 3.1.2R”, dated 1 March 2006. |
| 2. | Press release entitled, “Transaction by Persons Discharging Managerial Responsibilities Disclosure Rules DR 3.1.2R”, dated 6 March 2006. |
| 3. | Press release entitled, “AstraZeneca commences patent infringement litigation against IVAX”, dated 9 March 2006. |
| 4. | Press release entitled, “CRESTOR™ shows regression of coronary artery disease in a major clinical study”, dated 13 March 2006. |
| 5. | Press release entitled, “AstraZeneca Education Seminar on Merck arrangements“, dated 14 March 2006. |
| 6. | Press release entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 17 March 2006. |
| 7. | Press release entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 20 March 2006. |
| 8. | Press release entitled, “Notice of Annual General Meeting 2006 and Proposed Board Changes”, dated 20 March 2006. |
| 9. | Press release entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 24 March 2006. |
| 10. | Press release entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 27 March 2006. |
| 11. | Press release entitled, “AstraZeneca PLC Annual Information Update”, dated 27 March 2006. |
| 12. | Press release entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 28 March 2006. |
| 13. | Press release entitled, “Dealing by Directors Companies Act 1985 Sections 324 / 329”, dated 28 March 2006. |
| 14. | Press release entitled, “Dealing by Directors Companies Act 1985 Sections 324 / 329”, dated 28 March 2006. |
| 15. | Press release entitled, “Transaction by Persons Discharging Managerial Responsibilities Disclosure Rules DR 3.1.2R”, dated 28 March 2006. |
| 16. | Press release entitled, “Transaction by Persons Discharging Managerial Responsibilities Disclosure Rules DR 3.1.2R”, dated 28 March 2006. |
| 17. | Press release entitled, “Transaction by Persons Discharging Managerial Responsibilities Disclosure Rules DR 3.1.2R”, dated 28 March 2006. |
| 18. | Press release entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 29 March 2006. |
| 19. | Press release entitled, “Transaction by Persons Discharging Managerial Responsibilities Disclosure Rules DR 3.1.2R”, dated 29 March 2006. |
| 20. | Press release entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 30 March 2006. |
| 21. | Press release entitled, “Repurchase of Shares in AstraZeneca PLC”, dated 31 March 2006. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AstraZeneca PLC | ||||
| Date: | 4 April 2006 | By: | /s/ A C N Kemp | |
| Name: | A C N Kemp | |||
| Title: | Assistant Secretary | |||
Item 1
Dealing by Directors
Companies Act 1985 Sections 324/329
Transaction by Persons Discharging Managerial Responsibilities Disclosure Rules DR 3.1.2R
We hereby inform you that the interest of David R. Brennan, a Director of the Company, in the shares of AstraZeneca PLC has changed as detailed below. Mr Brennan has interests in both the Ordinary Shares and the American Depositary Shares (ADSs) of AstraZeneca PLC. One ADS equals one Ordinary Share.
On 24 February 2006, Mr Brennan received an allocation of 6,352 Ordinary Shares under the previously disclosed arrangements relating to his annual bonus for 2005 whereby he is required to defer a portion of the bonus earned into shares for a period of three years. The shares were allocated at a price of 2639 pence per share. Mr Brennan will become beneficially entitled to these shares on 24 February 2009.
On 24 February 2006, Mr Brennan received a scheduled distribution out of the AstraZeneca US Executive Deferral Plan, a unitised stock fund established in 2000, in which Mr Brennan, in common with other participating US executives, is deemed to have a notional interest in ADSs calculated by reference to the fund value and the closing price of AstraZeneca ADSs. Following this scheduled distribution on 24 February 2006, Mr Brennan had a notional interest in 70,387 ADSs within the AstraZeneca US Executive Deferral Plan by reference to the closing price on 24 February 2006 of US$46.14.
On 27 February 2006, Mr Brennan purchased, on his own account, additional ADSs to be held within the AstraZeneca US Executive Deferral Plan bringing his notional interest in ADSs held within the AstraZeneca US Executive Deferral Plan as at 27 February 2006 to 75,955 ADSs based on that day’s closing price of US$46.58.
In total, Mr Brennan now has an interest in 6,352 Ordinary Shares and 172,088 AstraZeneca ADSs, including the notional interest in ADSs in the AstraZeneca US Executive Deferral Plan referred to above.
G H R Musker
Company Secretary
1 March 2006
Item 2
Transaction by Persons Discharging Managerial Responsibilities Disclosure Rules DR 3.1.2R
We hereby inform you that on 3 March 2006, Tony Bloxham, Executive Vice-President, Human Resources, a person discharging managerial responsibilities, exercised an option over 5,231 AstraZeneca PLC USD0.25 Ordinary Shares at an option price of 1337 pence per share. The option was granted to Mr Bloxham in March 1996 under the Company’s 1994 Executive Share Option Scheme and was due to expire on 29 March 2006 if not exercised before then.
We also inform you that on 3 March 2006, Mr Bloxham sold the 5,231 shares acquired from the exercise at a price of 2649 pence per share.
G H R Musker
Company Secretary
6 March 2006
Item 3
AstraZeneca commences patent infringement litigation against IVAX
AstraZeneca announced today that it has filed a lawsuit in the United States District Court for the District of New Jersey against IVAX Corporation, IVAX Pharmaceuticals, Inc. and Zenith Laboratories, Inc. (collectively “IVAX”), and IVAX’s parent, Teva Pharmaceutical Industries Ltd. and its U.S. subsidiary, Teva Pharmaceuticals USA, for willful infringement of AstraZeneca’s patents protecting NEXIUM® (esomeprazole magnesium).
The lawsuit is in response to an Abbreviated New Drug Application filed by IVAX with the US Food and Drug Administration regarding IVAX’s intent to market a generic version of AstraZeneca’s NEXIUM in the US prior to the expiration of five AstraZeneca Patents: 5,714,504; 5,877,192; 6,369,085; 6,428,810; and 6,875,872. The expiration dates for these patents range from 2014 through to 2019.
AstraZeneca has full confidence in and will continue vigorously to defend and enforce its intellectual property rights protecting NEXIUM.
-Ends-
March 9, 2006
Media Enquiries:
CRESTORTM shows regression of
coronary artery disease in a major clinical study
The landmark ASTEROID study has demonstrated that two years treatment with CRESTORTM (rosuvastatin), 40mg once a day, reversed plaque build-up in the arteries of patients with evidence of coronary artery disease. This is the first time a statin has demonstrated regression of atherosclerosis in a major clinical study. The results of ASTEROID will be presented by Dr Steve Nissen (Chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic) at the 55th Annual Scientific Session of the American College of Cardiology (ACC) in Atlanta at 2:20pm EST today. Further details of the ASTEROID results will be made available following Dr Nissen’s presentation at the ACC.
Atherosclerosis results when a build-up of cholesterol, inflammatory cells and fibrous tissue forms areas in the artery wall called plaques. If these plaques rupture they can block blood flow to critical organs like the heart or the brain, and can lead to heart attack or stroke.
ASTEROID (A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden) was a 104-week, open label, single-arm, blinded endpoint study designed to study the effect of CRESTOR 40mg in 507 patients who had undergone coronary angiography and who had evidence of coronary artery disease (CAD). The plaque volume in the target coronary artery was measured at the initial catheterisation and again after two years of treatment. ASTEROID used intravascular ultrasound (IVUS) imaging to measure the effect on the change in plaque volume compared to baseline in the target vessel.
CRESTOR is indicated for the treatment of lipid disorders. CRESTOR is not indicated for atherosclerosis. The 40mg dose is the highest registered dose of CRESTOR. CRESTOR should be used according to the prescribing information, which contains recommendations for initiating and titrating therapy according to the individual patient profile. In most countries the usual recommended starting dose of CRESTOR is 5 or 10mg.
With over 40 million prescriptions written, CRESTOR has been prescribed to more than six million patients and has a safety profile in line with that of other marketed statins.
Intravascular Ultrasound (IVUS) is an invasive method of imaging arteries using high frequency sound waves that are transmitted and received inside the vessel being examined. It enables measurement of the volume of atheroma within the wall of the arteries by combining a series of cross-sectional images of the vessel over a predefined length. IVUS is
acknowledged as being among the most rigorously quantitative methodologies for assessing atheroma burden.
ASTEROID is part of AstraZeneca’s GALAXY Programme, designed to address important unanswered questions in statin research and to investigate the impact of CRESTOR on cardiovascular risk reduction and patient outcomes. The GALAXY Program has recruited over 50,000 subjects in more than 50 countries.
13 March 2006
Media Enquiries:
Edel McCaffrey, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033
Investor Relations:
Mina Blair, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
Ed Seage, Tel: +1 302 886 4065
Jorgen Winroth, Tel + 1 212 579 0506
-Ends-
AstraZeneca Education Seminar on Merck arrangements
On Tuesday, 14 March 2006 at 13:00GMT (14:00CET, 08:00EST) AstraZeneca will conduct an education seminar on the topic of the Company’s arrangements with Merck. Details for accessing the audio webcast of this seminar are listed below.
The objective for the seminar is to promote an understanding of the broad financial implications that are possible as a result of various termination scenarios provided for in the agreements, with a principal focus on the period beginning in 2008.
The slides to be used in the presentation are now available on the Company’s website, www.astrazeneca.com.
Much of the content in the slides has been excerpted from the AstraZeneca 2005 Annual Report and Form 20-F (pages 52-54, page 97, and pages 116-118).
Commenting on the seminar content, AstraZeneca Chief Financial Officer Jon Symonds said, “While the subject matter can appear complex, the conclusions are relatively straightforward. Based on our current
estimates, if Merck exercises the First Option in 2008, the net payment to Merck is unlikely to exceed the minimum value of $3.3 billion. Secondly, the estimated impact on our Profit and Loss account from 2008 onwards will be neutral to slightly
positive to earnings on a cash basis (that is excluding amortization of capitalized intangibles associated with the payment to Merck), and slightly negative on an accounting basis (including amortization of the intangible assets). The payment will
be made from existing cash resources, with no effect on our shareholder distribution policy.
There will be an audio webcast with sychronised slides. During the Q&A session you will be able to email questions to Jon Symonds.
Printable .pdf versions (b/w) of the slides are now available to download on the AstraZeneca Investors website (www.astrazeneca.com/node/investor.aspx).
A replay of the webcast will be available for viewing on the AstraZeneca Investors website from 15:30GMT on Tuesday 14 March. The indexed version will be available from 09:00GMT on Wednesday 15 March until 17:00GMT on Tuesday 28 March 2006.
14 March 2006
Media Enquiries:
Edel McCaffrey, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033
Investor Relations:
Mina Blair, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
Ed Seage, Tel: +1 302 886 4065
Jorgen Winroth, Tel + 1 212 579 0506
-Ends-
Item 6
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announced that on 16 March 2006, it purchased for cancellation 850,000 ordinary shares of AstraZeneca PLC at a price of 2890 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,576,655,260.
G H R Musker
Company Secretary
17 March 2006
Item 7
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announced that on 17 March 2006, it purchased for cancellation 650,000 ordinary shares of AstraZeneca PLC at a price of 2899 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,576,340,217.
G H R MuskerItem 8
NOTICE OF ANNUAL GENERAL MEETING 2006
AND PROPOSED BOARD CHANGES
AstraZeneca PLC announced today the publication of its Notice of Annual General Meeting for 2006 with a covering letter from the Chairman of the Board, and a Shareholders’ Circular and Proxy Form.
A copy of the Notice of AGM and Shareholders’ Circular is available on the Company's website www.astrazeneca.com and the documents are being despatched to shareholders from today. The date of the AGM is 27 April 2006.
With effect from the end of the AGM, Dame Bridget Ogilvie will retire from the Board after nine years’ service as a Non-Executive Director.
Professor Dame Nancy Rothwell FRS will be proposed by the Board for election as a new Non-Executive Director at the AGM. Professor Rothwell is currently Vice-President for Research at the University of Manchester. Further biographical details for Professor Rothwell can be found in the Notice of AGM and Shareholders’ Circular.
G H R Musker
Company Secretary
20 March 2006
Item 9
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announced that on 23 March 2006, it purchased for cancellation 800,000 ordinary shares of AstraZeneca PLC at a price of 2930 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,576,003,529.
G H R Musker
Company Secretary
24 March 2006
Item 10
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announced that on 24 March 2006, it purchased for cancellation 300,000 ordinary shares of AstraZeneca PLC at a price of 2946 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,575,840,890.
G H R Musker
Company Secretary
27 March 2006
Item 11
ASTRAZENECA PLC ANNUAL INFORMATION UPDATE
As required under the Prospectus (Directive 2003/71/EC) Regulations 2005and paragraph 5.2 of the Prospectus Rules, and following publication of the Annual Report and Form 20-F Information on 28 February 2006, AstraZeneca PLC is presenting its first Annual Information Update in relation to information that has been published or made available to the public between 1 February 2005 and 27 March 2006.
This Annual Information Update is also being made available on the Investors section of our website, www.astrazeneca.com.
The information referred to in this Annual Information Update was correct at the time it was published but may now be out of date.
1. Announcements made via a RIS
The documents listed below were published via a Regulatory Information Service on or around the dates indicated.
| Date | Description of Contents of Announcement | |
| 27/03/06 | Transaction in Own Shares | |
| 24/03/06 | Transaction in Own Shares | |
| 20/03/06 | Notice of AGM | |
| 20/03/06 | Transaction in Own Shares | |
| 17/03/06 | Transaction in Own Shares | |
| 14/03/06 | Seminar on Merck Arrangements | |
| 13/03/06 | Crestor | |
| 09/03/06 | Patent Writ | |
| 06/03/06 | Director/PDMR Shareholding | |
| 01/03/06 | Director/PDMR Shareholding | |
| 28/02/06 | Director/PDMR Shareholding | |
| 28/02/06 | Director/PDMR Shareholding | |
| 28/02/06 | Annual Report and Accounts | |
| 23/02/06 | Transaction in Own Shares | |
| 22/02/06 | Transaction in Own Shares | |
| 17/02/06 | Transaction in Own Shares | |
| 16/02/06 | Toprol-XL | |
| 14/02/06 | Exanta | |
| 13/02/06 | Transaction in Own Shares | |
| 10/02/06 | Transaction in Own Shares | |
| 09/02/06 | Transaction in Own Shares | |
| 06/02/06 | Transaction in Own Shares | |
| 03/02/06 | Transaction in Own Shares | |
| 02/02/06 | Final Results (in 3 parts) | |
| 01/02/06 | Notice of Results |
| 24/01/06 | Director/PDMR Shareholding | |
| 18/01/06 | Toprol-XL | |
| 03/01/06 | Seroquel | |
| 28/12/05 | Collaboration Agreement | |
| 23/12/05 | KuDOS Pharmaceuticals | |
| 22/12/05 | Collaboration | |
| 20/12/05 | Holding(s) in Company | |
| 16/12/05 | Transaction in Own Shares | |
| 15/12/05 | Director/PDMR Shareholding | |
| 15/12/05 | Transaction in Own Shares | |
| 14/12/05 | Transaction in Own Shares | |
| 09/12/05 | Transaction in Own Shares | |
| 08/12/05 | Licensing Agreement | |
| 08/12/05 | Transaction in Own Shares | |
| 07/12/05 | Transaction in Own Shares | |
| 02/12/05 | Director/PDMR Shareholding | |
| 02/12/05 | Transaction in Own Shares | |
| 01/12/05 | Transaction in Own Shares | |
| 30/11/05 | Holding(s) in Company | |
| 29/11/05 | Transaction in Own Shares | |
| 24/11/05 | Holding(s) in Company | |
| 24/11/05 | Transaction in Own Shares | |
| 23/11/05 | Holding(s) in Company | |
| 22/11/05 | Nexium | |
| 22/11/05 | Transaction in Own Shares | |
| 21/11/05 | Transaction in Own Shares | |
| 18/11/05 | Transaction in Own Shares | |
| 17/11/05 | Holding(s) in Company | |
| 17/11/05 | Transaction in Own Shares | |
| 16/11/05 | Transaction in Own Shares | |
| 15/11/05 | Transaction in Own Shares | |
| 14/11/05 | Transaction in Own Shares | |
| 11/11/05 | Transaction in Own Shares | |
| 10/11/05 | Transaction in Own Shares | |
| 09/11/05 | Seroquel | |
| 07/11/05 | Transaction in Own Shares | |
| 04/11/05 | Transaction in Own Shares | |
| 03/11/05 | Transaction in Own Shares | |
| 01/11/05 | Holding(s) in Company | |
| 31/10/05 | Zactima | |
| 31/10/05 | Transaction in Own Shares | |
| 28/10/05 | Holding(s) in Company | |
| 27/10/05 | 3rd Quarter Results (in 2 parts) | |
| 26/10/05 | Notice of Results | |
| 21/10/05 | Seroquel | |
| 18/10/05 | Nexium ANDA | |
| 03/10/05 | Transaction in Own Shares | |
| 29/09/05 | Transaction in Own Shares | |
| 28/09/05 | Seroquel ANDA | |
| 28/09/05 | Transaction in Own Shares |
| 23/09/05 | Regulatory Application | |
| 22/09/05 | Transaction in Own Shares | |
| 21/09/05 | Transaction in Own Shares | |
| 20/09/05 | Transaction in Own Shares | |
| 16/09/05 | Transaction in Own Shares | |
| 15/09/05 | Transaction in Own Shares | |
| 14/09/05 | Transaction in Own Shares | |
| 13/09/05 | Transaction in Own Shares | |
| 09/09/05 | Transaction in Own Shares | |
| 07/09/05 | Transaction in Own Shares | |
| 05/09/05 | Transaction in Own Shares | |
| 31/08/05 | Transaction in Own Shares | |
| 26/08/05 | Transaction in Own Shares | |
| 25/08/05 | Director/PDMR Shareholding | |
| 24/08/05 | Transaction in Own Shares | |
| 23/08/05 | Transaction in Own Shares | |
| 19/08/05 | Transaction in Own Shares | |
| 18/08/05 | Transaction in Own Shares | |
| 17/08/05 | Transaction in Own Shares | |
| 15/08/05 | Transaction in Own Shares | |
| 12/08/05 | Transaction in Own Shares | |
| 11/08/05 | Transaction in Own Shares | |
| 10/08/05 | Transaction in Own Shares | |
| 08/08/05 | Transaction in Own Shares | |
| 04/08/05 | Transaction in Own Shares | |
| 02/08/05 | Holding(s) in Company | |
| 28/07/05 | Interim Results (in 2 parts) | |
| 28/07/05 | Directorate Change | |
| 27/07/05 | Notice of Results | |
| 01/07/05 | Acquisition | |
| 01/07/05 | Transaction in Own Shares | |
| 30/06/05 | Director Shareholding | |
| 30/06/05 | Transaction in Own Shares | |
| 24/06/05 | Transaction in Own Shares | |
| 21/06/05 | Transaction in Own Shares | |
| 17/06/05 | Transaction in Own Shares | |
| 16/06/05 | Transaction in Own Shares | |
| 15/06/05 | Outcome of EC Investigation | |
| 10/06/05 | Transaction in Own Shares | |
| 08/06/05 | Transaction in Own Shares | |
| 07/06/05 | Transaction in Own Shares | |
| 06/06/05 | Transaction in Own Shares | |
| 02/06/05 | Transaction in Own Shares | |
| 01/06/05 | Director Shareholding | |
| 01/06/05 | Transaction in Own Shares | |
| 31/05/05 | Transaction in Own Shares | |
| 27/05/05 | Transaction in Own Shares | |
| 25/05/05 | Transaction in Own Shares | |
| 24/05/05 | Transaction in Own Shares | |
| 23/05/05 | Director Shareholding |
| 20/05/05 | Transaction in Own Shares | |
| 17/05/05 | Transaction in Own Shares | |
| 16/05/05 | Transaction in Own Shares | |
| 11/05/05 | Transaction in Own Shares | |
| 10/05/05 | Transaction in Own Shares | |
| 06/05/05 | Director Shareholding | |
| 06/05/05 | AGM Resolutions | |
| 06/05/05 | Transaction in Own Shares | |
| 05/05/05 | Director Shareholding | |
| 04/05/05 | Cerovive | |
| 28/04/05 | Result of AGM | |
| 28/04/05 | 1 st Quarter Results (in 2 parts) | |
| 27/04/05 | Notice of Results | |
| 07/04/05 | Director Shareholding | |
| 01/04/05 | Nexium | |
| 31/03/05 | Director Shareholding | |
| 29/03/05 | Director Shareholding | |
| 29/04/05 | Director Shareholding | |
| 23/03/05 | Notice of AGM | |
| 21/03/05 | Transaction in Own Shares | |
| 18/03/05 | Transaction in Own Shares | |
| 17/03/05 | Transaction in Own Shares | |
| 15/03/05 | Director Shareholding | |
| 14/03/05 | Directorate Change | |
| 14/03/05 | Transaction in Own Shares | |
| 10/03/05 | Transaction in Own Shares | |
| 08/03/05 | Transaction in Own Shares | |
| 03/03/05 | Holding(s) in Company | |
| 03/03/05 | Holding(s) in Company | |
| 02/03/05 | Transaction in Own Shares` | |
| 01/03/05 | Director Shareholding | |
| 28/02/05 | Transaction in Own Shares | |
| 25/02/05 | Transaction in Own Shares | |
| 24/02/05 | Transaction in Own Shares | |
| 23/02/05 | Regulatory Approval | |
| 22/02/05 | Annual Report and Accounts | |
| 21/02/05 | Transaction in Own Shares | |
| 15/02/05 | Transaction in Own Shares | |
| 14/02/05 | Transaction in Own Shares | |
| 11/02/05 | Transaction in Own Shares | |
| 10/02/05 | Transaction in Own Shares | |
| 07/02/05 | Transaction in Own Shares | |
| 04/02/05 | Transaction in Own Shares | |
| 02/02/05 | Transaction in Own Shares |
All of the above documents are available for download on the Prices and News section of the London Stock Exchange website, www.londonstockexchange.com.
2. Documents filed at Companies House
All of the documents below were filed with the Registrar of Companies in England and Wales on or around the dates indicated.
| Date | Document type | |
| 08/03/06 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 08/03/06 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 27/01/06 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 11/01/06 | Form 88(2)R – Return of an Allotment of Shares | |
| 11/01/06 | Form 88(2)R– Return of an Allotment of Shares | |
| 11/01/06 | Form 88(2)R– Return of an Allotment of Shares | |
| 11/01/06 | Form 88(2)R– Return of an Allotment of Shares | |
| 11/01/06 | Form 88(2)R– Return of an Allotment of Shares | |
| 04/01/06 | Form 288b – Director Resigned | |
| 06/01/06 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 06/01/06 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 21/12/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 21/12/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 21/12/06 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 13/12/06 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 13/12/06 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 13/12/06 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 14/11/05 | Interim Accounts made up to 30/09/05 | |
| 27/10/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 27/10/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 24/10/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 24/10/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 24/10/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 24/10/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 24/10/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 24/10/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 24/10/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 11/10/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 11/10/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 11/10/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 11/10/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 14/09/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 14/09/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 14/09/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 22/08/05 | Interim Accounts made up to 30/06/05 | |
| 09/08/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 02/08/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 02/08/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 02/08/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 20/07/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 20/07/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 08/07/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 08/07/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 08/07/05 | Form 169 – Return by a Company Purchasing its Own Shares |
| 08/07/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 08/07/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 30/06/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 09/06/05 | Form 363s – Return made up to 15/05/05 | |
| 06/06/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 06/06/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 06/06/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 06/06/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 06/06/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 06/06/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 06/06/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 06/06/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 06/06/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 06/06/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 06/06/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 06/06/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 06/06/05 | Form 88(2)R – Return of an Allotment of Shares | |
| 01/06/05 | Group of Companies’ Accounts made up to 31/12/04 | |
| 12/05/05 | Resolution to disapply pre-emption rights, to give authority to allot shares and to ratify financial assistance for the acquisition of shares | |
| 29/04/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 21/04/05 | Form 288a – Director Appointed | |
| 31/03/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 31/03/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 31/03/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 10/03/05 | Form 288a – Director Appointed | |
| 02/03/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 02/03/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 01/03/05 | Form 169 – Return by a Company Purchasing its Own Shares | |
| 01/03/05 | Form 169 – Return by a Company Purchasing its Own Shares |
All of the documents above are available for download from the Companies House website at www.companieshouse.gov.uk, or can be obtained from Companies House, Crown Way, Maindy, Cardiff, CF14 3UZ.
3. Documents submitted to the FSA
All the documents below were submitted to the FSA on or around the dates indicated.
| Date | Document | |
| 16/03/06 | Notice of AGM 2006 | |
| 16/03/06 | Annual Report and Form 20-F Information 2005 | |
| 16/03/06 | Annual Review 2005 | |
| 16/03/06 | Summary CR Report 2005 | |
| 04/05/05 | Resolutions after AGM 2005 | |
| 17/03/05 | Notice of AGM 2005 | |
| 17/03/05 | Annual Report and Form 20-F Information 2004 | |
| 17/03/05 | Annual Review 2004 | |
| 17/03/05 | Summary CR Report 2004 |
Documents submitted to the FSA can be viewed at the Document Viewing Facility situated at The Financial Services Authority, 25 The North Colonnade, Canary Wharf, London, E14 5HS.
The Notices of AGM, Annual Reports and Form 20-F Information, Annual Reviews and Summary CR Reports are also available via the Investors section of our website, www.astrazeneca.com.
4. Documents lodged with the Securities and Exchange Commission
The documents listed below were filed with the SEC on or around the dates indicated.
| Date | Document | |
| 23/03/06 | Annual Reports | |
| 14/03/06 | Quarterly Reports | |
| 14/03/06 | Quarterly Reports | |
| 10/03/06 | Quarterly Reports | |
| 10/02/06 | Insider Trading | |
| 09/02/06 | Quarterly Reports | |
| 06/02/06 | Quarterly Reports | |
| 06/01/06 | Quarterly Reports | |
| 02/12/05 | Quarterly Reports | |
| 08/11/05 | Quarterly Reports | |
| 05/10/05 | Quarterly Reports | |
| 09/09/05 | Quarterly Reports | |
| 05/08/05 | Quarterly Reports | |
| 05/07/05 | Quarterly Reports | |
| 29/06/05 | Annual Reports | |
| 06/06/05 | Quarterly Reports | |
| 10/05/05 | Registration Statements | |
| 06/05/05 | Quarterly Reports | |
| 21/03/05 | Annual Reports | |
| 24/03/05 | Quarterly Reports |
All of the documents above are available for viewing on the Investor section of our website, www.astrazeneca.com.
5. Further Information
Further information about AstraZeneca PLC can be found at our website, www.astrazeneca.com.
Item 12
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announced that on 27 March 2006,
it purchased for cancellation 750,000 ordinary shares of AstraZeneca PLC at a price of 2925 pence per share. Upon the cancellation of these shares,
the number of shares in issue will be 1,575,500,477.
Item 13
Dealing by Directors
Companies Act 1985 Sections 324/329
We hereby inform you that on 24 March 2006 the following Directors of AstraZeneca PLC were granted options under the AstraZeneca Share Option Plan over the Company’s USD0.25 Ordinary Shares.
| Name of Director |
Number of shares over which option is granted |
Exercise price per share |
Period when exercisable |
Total number of shares under option | ||||
| D R Brennan | 87,731 | 2975p | 24.3.09-23.3.16 | See below | ||||
| J R Symonds | 50,862 | 2975p | 24.3.09-23.3.16 | 363,420 | ||||
| J S Patterson | 41,552 | 2975p | 24.3.09-23.3.16 | 238,187 |
The options will become exercisable on 24 March 2009 subject to certain performance conditions. The conditions, which will not be subject to any retesting, are that the earnings per share of the Company must increase by the increase in the UK Retail Prices Index plus 5% per annum on average over three years, and that no significant unforeseen event has taken place which, in the reasonable opinion of the Remuneration Committee, has resulted in major reputational damage to AstraZeneca, and the circumstances of which are exceptional enough to justify the option not vesting and becoming exercisable. Failure to satisfy either or both of these conditions will result in the lapse of the option in its entirety.
David R Brennan, a Director of the Company, has previously received grants of options over the Company’s American Depositary Shares (ADSs). One ADS equals one Ordinary Share. Following the grant of options referred to above, David Brennan has options over 87,731 Ordinary Shares and 440,643 ADSs.
G H R MuskerItem 14
Dealing by DirectorsWe hereby inform you that on 24 March 2006 the following Directors of AstraZeneca PLC were each granted an award under the terms of the AstraZeneca Performance Share Plan over the Company’s USD0.25 Ordinary Shares.
| Name of Director | Target number of shares awarded | Award price per share | Normal vesting date | Total interest in shares after this award | Percentage of shares in issue | |||||
| D R Brennan | 73,109 | 2975p | 24 March 2009 | See below | See below | |||||
| J R Symonds | 41,646 | 2975p | 24 March 2009 | 108,430 | 0.007% | |||||
| J S Patterson | 32,319 | 2975p | 24 March 2009 | 81,390 | 0.005% |
The AstraZeneca Performance Share Plan was approved by shareholders at the Company’s AGM in 2005. Awards made under the Plan may not generally vest before the third anniversary of the relevant date of grant nor unless the specified performance target(s) have been met at the end of the three year period which, for this award, is 1 January 2006 to 31 December 2008.
The performance target that applies to this award is the Company’s Total Shareholder Return (“TSR”) compared to the TSR of a selected peer group of 12 other pharmaceutical companies. The actual number of shares to which a participant may become unconditionally entitled will depend on the extent to which the performance target(s) have been met. A summary of the Plan, including a more detailed explanation of the performance target(s), can be found in the AstraZeneca Annual Report and Form 20-F Information 2005 which is available on the Company’s website www.astrazeneca.com.
On 25 March 2005, David R Brennan, a Director of the Company, became unconditionally entitled to a final award of 31,780 American Depositary Shares (ADSs) on the partial vesting of an original target award of 33,104 ADSs, which were awarded to him in March 2003 under the terms of the AstraZeneca US Executive Performance Share Plan. Mr Brennan has ceased to have an interest in the 1,324 ADSs of the original target award that did not vest. The closing price of AstraZeneca ADSs on 24 March 2006 was US$51.73. One ADS equals one Ordinary Share. In total, Mr Brennan now has an interest in 79,461 Ordinary Shares and 170,764 ADSs which together represent approximately 0.016% of the number of shares currently in issue.
G H R MuskerItem 15
Transaction by Persons Discharging Managerial Responsibilities Disclosure Rules DR 3.1.2R
We hereby inform you that on 24 March 2006 the following individuals, who are all persons discharging managerial responsibilities, were granted options under the AstraZeneca Share Option Plan over the Company’s USD0.25 Ordinary Shares or, in the case of A Zook, over the Company’s American Depositary Shares (ADSs). One ADS equals one Ordinary Share
| Name of individual | Number of shares over which option is granted | Exercise price per share | Period when exercisable | |||
| B Angelici | 36,048 | 2975p | 24.3.09-23.3.16 | |||
| A P Bloxham | 18,519 | 2975p | 24.3.09-23.3.16 | |||
| J Lundberg | 23,068 | 2975p | 24.3.09-23.3.16 | |||
| M Nicklasson | 23,092 | 2975p | 24.3.09-23.3.16 | |||
| B J Thorpe | 18,496 | 2975p | 24.3.09-23.3.16 | |||
| A Zook | 51,676 | US$51.73 | 24.3.09-23.3.16 |
The options will become exercisable on 24 March 2009 subject to certain performance conditions. The conditions, which will not be subject to any retesting, are that the earnings per share of the Company must increase by the increase in the UK Retail Prices Index plus 5% per annum on average over three years, and that no significant unforeseen event has taken place which, in the reasonable opinion of the Remuneration Committee, has resulted in major reputational damage to AstraZeneca, and the circumstances of which are exceptional enough to justify the option not vesting and becoming exercisable. Failure to satisfy either or both of these conditions will result in the lapse of the option in its entirety.
G H R Musker
Company Secretary
28 March 2006
Item 16
Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rules DR 3.1.2R
We hereby inform you that on 27 March 2006, Anthony Zook, Executive Vice-President, North America, a person discharging managerial responsibilities, exercised an option over 30,990 AstraZeneca PLC American Depositary Shares (ADSs) at an option price of $35.16 per ADS. One ADS equals one Ordinary Share.
We also inform you that on 27 March 2006, Mr
Zook sold 24,790 of the ADSs acquired from the exercise at an average
price of $50.39 per ADS. The sale was effected to cover the cost of
exercising the option and to meet certain immediate tax liabilities.
Mr Zook has retained the remaining 6,200 ADSs.
Item 17
Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rules DR 3.1.2R
We hereby inform you that on 24 March 2006, the following individuals, who are all persons discharging managerial responsibilities, were each granted an award under the terms of the AstraZeneca Performance Share Plan over the Company’s USD0.25 Ordinary Shares or, in the case of A Zook, over the Company’s American Depositary Shares (ADSs). One ADS equals one Ordinary Share
| Name of individual | Target number of shares awarded | Award price per share | Normal vesting date | |||
| B Angelici | 26,781 | 2975p | 24 March 2009 | |||
| A P Bloxham | 13,847 | 2975p | 24 March 2009 | |||
| J Lundberg | 18,475 | 2975p | 24 March 2009 | |||
| M Nicklasson | 18,473 | 2975p | 24 March 2009 | |||
| B J Thorpe | 13,834 | 2975p | 24 March 2009 | |||
| A Zook | 37,624 | US$51.73 | 24 March 2009 |
The AstraZeneca Performance Share Plan was approved by shareholders at the Company’s AGM in 2005. Awards made under the Plan may not generally vest before the third anniversary of the relevant date of grant nor unless the specified performance target(s) have been met at the end of the three year period which, for this award, is 1 January 2006 to 31 December 2008.
The performance target that applies to this award is the Company’s Total Shareholder Return (“TSR”) compared to the TSR of a selected peer group of 12 other pharmaceutical companies. The actual number of shares to which a participant may become unconditionally entitled will depend on the extent to which the performance target(s) have been met. A summary of the Plan, including a more detailed explanation of the performance target(s), can be found in the AstraZeneca Annual Report and Form 20-F Information 2005 which is available on the Company’s website www.astrazeneca.com.
On 25 March 2005, Anthony Zook, Executive Vice-President, North America, became unconditionally entitled to a final award of 11,494 American Depositary Shares (ADSs) on the partial vesting of an original target award of 11,973 ADSs, which were awarded to him in March 2003 under the terms of the AstraZeneca US Executive Performance Share Plan. Mr Zook has ceased to have an interest in the 479 ADSs of the original target award that did not vest. The closing price of AstraZeneca ADSs on 24 March 2006 was US$51.73. One ADS equals one Ordinary Share.
G H R Musker
Company Secretary
28 March 2006
Item 18
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announced that on 28 March 2006, it purchased for cancellation
500,000 ordinary shares of AstraZeneca PLC at a price of 2902 pence per share.
Upon the cancellation of these shares, the number of shares in issue will be 1,578,537,545.
Item 19
Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rules DR 3.1.2R
We hereby inform you that on 28 March 2006, Martin Nicklasson, Executive Vice-President, Global Marketing and Business Development, a person discharging managerial responsibilities, sold 273 AstraZeneca PLC USD0.25 Ordinary Shares at a price of 2914 pence per share.
Item 20
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announced that on 29 March 2006, it purchased for cancellation 350,000 ordinary shares of AstraZeneca PLC at a price of 2910 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,578,623,700.
Item 21
REPURCHASE OF SHARES IN ASTRAZENECA PLC
AstraZeneca PLC announced that on 30 March 2006, it purchased for cancellation 300,000 ordinary shares of AstraZeneca PLC at a price of 2914 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,578,466,401.